Amplify Weight Loss Drug & Treatment ETF Rating $22.76 -0.48 (-2.07%) (As of 12/20/2024 04:33 PM ET) Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatings Amplify Weight Loss Drug & Treatment ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.THNR Aggregate RatingModerate Buy 2.78Holdings in THNR have an aggregate rating of Moderate Buy based on 196 analyst ratings issued in the past year covering 16 companies (69.5% of the portfolio).THNR Aggregate Price Target$22.76High Prediction$22.76Average Prediction$22.76Low Prediction$22.76Holdings in THNR have an aggregate price target of $22.76 and a range of $22.76 to $22.76 covering 16 companies (69.5% of the portfolio).THNR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy8 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Amplify Weight Loss Drug & Treatment ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 16 THNR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings14.70%LLYEli Lilly and Company$767.76+1.3%4.9941 of 5 stars2.81$1,002.22 30.5%21Gap UpHigh Trading Volume13.67%NVONovo Nordisk A/S$85.00-17.8%3.7173 of 5 stars3.00$150.40 76.9%7Analyst UpgradeNews CoverageGap DownHigh Trading Volume5.07%PFEPfizer$26.36+2.3%4.9711 of 5 stars2.47$32.14 21.9%17Analyst ForecastOptions VolumeAnalyst RevisionHigh Trading Volume5.00%MRKMerck & Co., Inc.$98.05-1.5%4.9882 of 5 stars2.71$127.13 29.7%21Analyst DowngradeHigh Trading Volume4.94%TMOThermo Fisher Scientific$524.05+1.4%4.7588 of 5 stars2.86$652.30 24.5%214.86%AZNAstraZeneca$65.35+1.4%4.0456 of 5 stars2.91$89.75 37.3%114.83%AMGNAmgen$263.38+0.8%4.4622 of 5 stars2.40$319.67 21.4%25Analyst DowngradeGap UpHigh Trading Volume4.52%WSTWest Pharmaceutical Services$331.40+1.3%4.966 of 5 stars2.80$437.75 32.1%5High Trading Volume3.67%TEVATeva Pharmaceutical Industries$22.09+3.7%1.8723 of 5 stars2.75$20.88 -5.5%8Analyst DowngradeOptions VolumeNews Coverage2.34%GPCRStructure Therapeutics$27.90-6.9%2.3713 of 5 stars3.00$86.50 210.0%7Analyst ForecastNews CoverageGap UpHigh Trading Volume2.24%VKTXViking Therapeutics$42.25+1.8%4.2972 of 5 stars3.15$106.75 152.7%13Analyst ForecastGap Up2.12%CTLTCatalent$63.482.7663 of 5 stars2.00$63.40 -0.1%70.98%HIMSHims & Hers Health$26.20-0.6%3.3859 of 5 stars2.41$22.80 -13.0%17Analyst ForecastInsider TradeNews Coverage0.26%ALTAltimmune$8.25+0.9%1.9527 of 5 stars2.88$20.00 142.4%8News Coverage0.21%OPKOPKO Health$1.54-1.9%4.1694 of 5 stars3.00$2.75 78.6%3Analyst Upgrade0.12%TERNTerns Pharmaceuticals$5.86-3.1%4.2467 of 5 stars2.80$18.30 212.3%5Positive NewsGap DownHigh Trading Volume This page (NYSEARCA:THNR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Weight Loss Drug & Treatment ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Weight Loss Drug & Treatment ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
